<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65292">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01708538</url>
  </required_header>
  <id_info>
    <org_study_id>Rush CXL</org_study_id>
    <nct_id>NCT01708538</nct_id>
  </id_info>
  <brief_title>The Effects of Corneal Collagen Cross-linking</brief_title>
  <official_title>Phase III Study of Corneal Collagen Cross-linking Using Two Different Techniques.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush Eye Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rush Eye Associates</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The corneal collagen cross-linking treatment has been used with increasing success to treat
      corneal dystrophies such as &quot;keratoconus.&quot; Recent advances have allowed different techniques
      for performing this cross-linking treatment. This study investigates the effects of corneal
      cross-linking using different surgical techniques.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Best corrected Snellen acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Keratometry measurements</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Average curvature of the cornea</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Corneal Ectasia Disorders Including Keratoconus</condition>
  <arm_group>
    <arm_group_label>Epithelium on</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epi not removed during CXL treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epithelium off</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epi removed before CXL treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CXL</intervention_name>
    <description>corneal crosslinking</description>
    <arm_group_label>Epithelium on</arm_group_label>
    <arm_group_label>Epithelium off</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 10-70, willing to participate, diagnosis of corneal ectasia disorder

        Exclusion Criteria:

          -  Unwilling or unable to participate in trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sloan W Rush, MD</last_name>
    <phone>806-353-0125</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Rush Eye Associates</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunday Fowler</last_name>
      <phone>806-353-0125</phone>
    </contact>
    <investigator>
      <last_name>Sloan W Rush, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 16, 2012</lastchanged_date>
  <firstreceived_date>October 15, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>keratoconus, corneal collagen crosslinking, riboflavin, corneal ectasia</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dilatation, Pathologic</mesh_term>
    <mesh_term>Keratoconus</mesh_term>
    <mesh_term>Corneal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
